Consumer Health News and Research

RSS

Some pharmacists not adhering to therapeutic guidelines, QUT study finds

As the role of pharmacies in providing front-line public health services grows, a QUT study has raised concerns that some are not adhering to therapeutic guidelines when distributing pharmaceuticals.

19 Jul 2019

Some pharmacists fail to adhere to therapeutic guidelines, highlights study

As the role of pharmacies in providing front-line public health services grows, a QUT study has raised concerns that some are not adhering to therapeutic guidelines when distributing pharmaceuticals.

19 Jul 2019

A Portable Solution for the On-scene Identification of Kratom

Zachary Lawton describes a portable GC-MS solution for the identification of Kratom and other drugs that cannot be identified using traditional colorimetric tests.

From Pittcon 16 Jul 2019

Common bacterial pathogen of diarrhea diseases unknown to many people

Overall though, people are not as concerned as they were in the last survey in summer 2018.

17 May 2019

INTERPHEX 2019 Celebrates 40 years of Delivering Technology Innovation to Industry

INTERPHEX has been the leading pharmaceutical, biotechnology, device development, and manufacturing event for 40 years.

From Interphex 5 Apr 2019

Early marker of cardiac damage triggered by cancer treatment identified

Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.

19 Feb 2019

Experts discuss various aspects on health risks posed by fumigated containers

Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.

17 Jan 2019

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

New patient-centric website launched in Europe to empower people with chronic conditions

Teva Pharmaceutical Industries Ltd. today announced the European launch of Life Effects (https://lifeeffects.teva), a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis Congress in Berlin.

12 Oct 2018

Teva announces European launch of patient-centric website

Teva Pharmaceutical Industries Ltd. today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis Congress in Berlin.

11 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA

Pfizer Inc. announced today that its 20-Valent Pneumococcal Conjugate Vaccine candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. Pfizer expects to start Phase 3 trials in a few months.

20 Sep 2018

New platform examines infectious pathogens that may spread from animals to humans

Large-scale food scares like BSE and dioxin-contaminated eggs raised awareness about the health risks posed when a link in the food chain becomes compromised.

20 Sep 2018

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).

30 Aug 2018

FDA grants Breakthrough designation to Dthera Sciences' development-stage product for Alzheimer's

Dthera™ Sciences, the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.

24 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Pfizer Inc. and Eli Lilly and Company today announced that a 16-week Phase 3 study in patients with osteoarthritis pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints.

19 Jul 2018

Insight into health risks of tattoo inks

"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.

3 Jul 2018